Low molecular weight heparin in coronary stenting

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Coronary stent placement is a common procedure to treat arterial blockages.
• Conventional post-stent therapy involves a complex five-drug regimen.
• There is a need for simpler, effective anti-thrombotic strategies after stenting.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel combination therapy for elective stent placement.
• To compare enoxaparin, ticlopidine, and acetylsalicylic acid (ASA) against a conventional five-drug regimen.
• To assess the impact on bleeding, vascular complications, and thrombotic events.

Main Methods:

• A pilot clinical study (ENTICES) involving patients undergoing elective stent placement.
• Randomized assignment to either the novel enoxaparin-based regimen or the conventional therapy.
• Comparison of composite rates for bleeding, vascular complications, and major adverse cardiovascular events at 30 days and six months.

Main Results:

• The enoxaparin, ticlopidine, and ASA group (79 patients) showed significantly lower rates of in-hospital bleeding and vascular complications (5% vs. 16%; P=0.005).
• A significantly lower composite endpoint rate (death, MI, stent thrombosis, urgent revascularization) at 30 days was observed (5% vs. 20%; P=0.001).
• The novel regimen demonstrated a significantly lower incidence of stent thrombosis within 30 days (0% vs. 7%; P=0.04) with similar six-month outcomes for death or repeat angioplasty.

Conclusions:

• The ENTICES pilot study suggests that enoxaparin, ticlopidine, and ASA is a safe and effective alternative to conventional therapy after elective stent placement.
• This combination regimen significantly reduces bleeding, vascular complications, and thrombotic events, including stent thrombosis.
• The ongoing ATLAST trial will further investigate the benefits of enoxaparin in high-risk patients for stent thrombosis.